跳至主要内容
临床试验/ISRCTN26119679
ISRCTN26119679已完成未知

A double blind randomised controlled trial of post-operative low molecular weight heparin bridging therapy versus placebo bridging therapy for patients who are at high risk for arterial thromboembolism

ondon Health Sciences Centre (Canada)0 个研究点目标入组 1,773 人开始时间: 2008年6月4日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
1,773

研究概览

简要总结

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Informed consent
  • 2. Patients of either sex, 18 years and older, with prosthetic heart valves receiving long-term oral anticoagulation with warfarin, or
  • 3. Patients with atrial fibrillation and a major risk factor (previous transient ischaemic attack (TIA) or stroke, high blood pressure, diabetes, 75 years and older, moderate/severe left ventricle dysfunction), who require elective non-cardiac surgery or an invasive procedure with reversal of their anticoagulant therapy

排除标准

  • 1. Evidence of active bleeding prior to stopping warfarin
  • 2. Platelet count less than 100 x 10^9/L
  • 3. Spinal or neurosurgery
  • 4. Life expectancy less than three months
  • 5. Serum creatinine greater than 150 umol/L
  • 6. Patients requiring cardiac surgery
  • 7. Multiple prosthetic valves or Starr-Edwards valves or prosthetic valves with a history of stroke or TIA

研究者

发起方
ondon Health Sciences Centre (Canada)

相似试验